Open AccessPhylogeny and drug resistance of HIV PR gene among HIV patients receiving RT inhibitors in Iran
Author(s) -
Kazem Baesi,
Majedeh Moradbeigi,
Mehrdad Ravanshad,
Ashrafolnesa Baghban
Publication year - 2016
Publication title -
asian pacific journal of tropical biomedicine/asian pacific journal of tropical biomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.507
H-Index - 61
eISSN - 2588-9222
pISSN - 2221-1691
DOI - 10.1016/j.apjtb.2015.12.020
Subject(s) - reverse transcriptase , drug resistance , virology , medicine , drug , protease , hiv drug resistance , transmission (telecommunications) , lentivirus , human immunodeficiency virus (hiv) , gene , biology , polymerase chain reaction , antiretroviral therapy , viral disease , viral load , pharmacology , enzyme , genetics , biochemistry , electrical engineering , engineering
Objective: To survey the level and patterns of reverse transcriptase-based drug resistance and subtype distribution among antiretroviral-treated HIV-infected patients receiving only reverse transcriptase inhibitors in Iran.Methods: A total of 25 samples of antiretroviral therapy experienced patients with no history of using protease inhibitors were collected. After RNA extraction, reverse transcriptase-nested PCR was performed. The final products were sequenced and then analysed for drug-resistant mutations and subtypes.Results: No drug resistant mutations were observed among the 25 subjects. The results showed the following subtypes among patients: CRF 35_AD (88%), CRF 28_BF (8%), and CRF 29_BF (4%).Conclusions: A significant increase in drug resistance has been noted in recently-infected patients worldwide. Subtype distributions are needed to perform properly-designed surveillance studies to continuously monitor rates and patterns of transmitted drug resistance and subtypes to help guide therapeutic approaches and limit transmission of these variants